Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in HFPEF (SPIRRIT)
NCT02901184Phase 3Recruiting
- Sponsor
- Uppsala University
- Start
- Nov 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of spironolactone in heart failure with preserved ejection fraction (HFpEF), sponsored by Uppsala University. Started Nov 2017; status: recruiting.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02901184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901184.